Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 302 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years... May 15, 2024 Reflections on My First Year as NCI Director November 1, 2018 Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75 September 17, 2019 Improving cancer care for the LGBTQ+ community July 26, 2021 Load more HOT NEWS ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer? COVID-19: “It could take months to build research up again” Conducting Phase I Clinical Trials During the COVID-19 Pandemic When You and Your Child Have VHL: 8 Ways to Cope
